Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit

• Published in: The New England journal of medicine Vol. 386; no. 25; pp. 2387 - 2398
• Main Authors: Lamontagne, François, Masse, Marie-Hélène, Menard, Julie, Sprague, Sheila, Pinto, Ruxandra, Heyland, Daren K., Cook, Deborah J, Battista, Marie-Claude, Day, Andrew G., Guyatt, Gordon H., Kanji, Salmaan, Parke, Rachael, McGuinness, Shay P., Tirupakuzhi Vijayaraghavan, Bharath-Kumar, Annane, Djillali, Cohen, Dian, Arabi, Yaseen M., Bolduc, Brigitte, Marinoff, Nicole, Rochwerg, Bram, Millen, Tina, Meade, Maureen O., Hand, Lori, Watpool, Irene, Porteous, Rebecca, Young, Paul J., D’Aragon, Frederick, Belley-Cote, Emilie P., Carbonneau, Elaine, Clarke, France, Maslove, David M., Hunt, Miranda, Chassé, Michaël, Lebrasseur, Martine, Lauzier, François, Mehta, Sangeeta, Quiroz-Martinez, Hector, Rewa, Oleksa G., Charbonney, Emmanuel, Seely, Andrew J.E., Kutsogiannis, Demetrios J., LeBlanc, Remi, Mekontso-Dessap, Armand, Mele, Tina S., Turgeon, Alexis F., Wood, Gordon, Kohli, Sandeep S., Shahin, Jason, Twardowski, Pawel, Adhikari, Neill K.J.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 23.06.2022
• Subjects: Adult; Anaphylaxis; Ascorbic acid; Ascorbic Acid - adverse effects; Biomarkers; Body weight; Clinical Medicine; Consent; Critical Care; Critical Care General; Death; Emergency Medicine; Emergency Medicine General; Hospital-Based Clinical Medicine; Humans; Hypoglycemic Agents - therapeutic use; Infections; Infectious Disease; Infectious Disease General; Intensive care; Intensive Care Units; Intravenous administration; Life Sciences; Mechanical ventilation; Mortality; Multiple Organ Failure; Placebos; Pulmonary; Quality of Life; Sepsis; Sepsis - drug therapy; Severe acute respiratory syndrome coronavirus 2; Vasoconstrictor Agents - adverse effects; Vitamin C; Vitamins - adverse effects; Canada

In this trial of intravenous vitamin C in adult patients with sepsis, those who received a vitamin C infusion had a higher risk of death or persistent organ dysfunction at 28 days than those who received placebo.